Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study.

Academic Article

Abstract

  • BACKGROUND: Twenty-seven ovarian cancer patients who failed chemotherapy entered a phase I/II trial of intraperitoneal 177Lu-CC49 antibody. METHODS: Patients had disease confined to the abdominal cavity +/- retroperitoneal lymph nodes, adequate organ function, and no previous radiation. RESULTS: The most common side effects were delayed, transient arthralgia (10/27) and marrow suppression with 1.665 GBq/m2 (45 mCi/m2), which was considered the maximum tolerated dose. One of thirteen patients with gross disease had >50% tumor reduction after therapy, whereas most others with gross disease progressed (one went off study with stable disease at 11 weeks). Seven of nine patients with <1-cm nodules progressed in < or =21 months, and two of nine remain without evidence of disease at 4 to 5 months. Of patients with microscopic or occult disease, one relapsed at 10 months and four of five remain without evidence of disease at >6 to 35 months. CONCLUSIONS: Marrow suppression was the dose-limiting toxic effect of intraperitoneal immunotherapy with 177Lu-CC49. Antitumor effects were noted against chemotherapy-resistant ovarian cancer, even at lower dose levels, and resulted in prolonged disease-free survival of most patients with microscopic disease. This form of treatment deserves further study.
  • Published In

    Keywords

  • Adult, Aged, Antibodies, Monoclonal, Arthralgia, Bone Marrow, Disease Progression, Dose-Response Relationship, Radiation, Female, Humans, Injections, Intraperitoneal, Lutetium, Middle Aged, Ovarian Neoplasms, Platelet Count, Radioimmunotherapy, Radioisotopes
  • Digital Object Identifier (doi)

    Author List

  • Alvarez RD; Partridge EE; Khazaeli MB; Plott G; Austin M; Kilgore L; Russell CD; Liu T; Grizzle WE; Schlom J
  • Start Page

  • 94
  • End Page

  • 101
  • Volume

  • 65
  • Issue

  • 1